Mircochip helps blind cats see

Article

A veterinary ophthalmologist from the USA is working on a microchip implant to help blind cats see.

A veterinary ophthalmologist from the University of Missouri, Columbia, USA is working on a microchip implant to help blind cats see, which may eventually be used in humans too.

Kristina Narfstrom works primarily with Abyssinian and Persian cats who are often affected by retinitis pigmentosa. Cat's eyes are good models as they are similar to the human eye in size and construction and share many of the same diseases that affect humans.

Implantation involves making two small cuts in the sclera and, after removing the vitreous, creating a small blister in the retina and a small opening for the microchip, which is just 2 mm in diameter and 23 µm thick. The chip contains several thousand microphotodiodes that react to light and produce small electrical impulses in parts of the retina.

It is hoped that this technology will be of benefit, not just to cats, but for humans and other animals too.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.